Waimea

Researchers are evaluating whether Pain Ease vapocoolant spray can reduce the pain caused by lidocaine injections during the insertion of Nexplanon, a type of etonogestrel implant used for birth control. This randomized controlled trial focuses on female patients aged 14 years and older who are scheduled for Nexplanon insertion. The study aims to compare the pain levels experienced with the vapocoolant spray versus a placebo spray during the procedure. Participants will be randomly assigned to one of two groups one group will receive Pain Ease vapocoolant spray applied to the skin for up to 5 seconds before the lidocaine injection, while the other group will receive a saline spray as a placebo. The vapocoolant spray is already approved for reducing pain from needle sticks in other settings and is being tested here specifically for Nexplanon insertion. The spray is applied just before the lidocaine injection and the Nexplanon insertion is performed as usual. During the study visit, pain levels will be assessed immediately after the lidocaine injection and again after the entire procedure. Patient satisfaction will also be measured right after the procedure. Eligible patients will provide written consent before participation. The study includes monitoring for any potential reactions to the sprays and ensures the procedure is done safely. Total participation lasts for the duration of the office visit when the Nexplanon insertion takes place.